VASCULAR COGNITIVE IMPAIRMENT: FROM PATHOGENESIS TO TREATMENT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The term vascular cognitive impairments (VCI) defines dementia and cognitive impairment no dementia, which are pathogenetically associated with cerebral vessel damage. The paper considers the etiology, pathogenesis, criteria for instrumental and clinical diagnosis, as well as VCI. The relationship between VCI and neurodegenerative diseases is discussed separately.

Full Text

Restricted Access

About the authors

O. Tkacheva

Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Professor MD Moscow

N. Runikhina

Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Professor MD Moscow

M. Cherdak

Russian Gerontology Research and Clinical Center, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: maria.cherdak@yandex.ru
Candidate of Medical Sciences Moscow

References

  1. Hachinski V. Stroke: a global agenda (Victor and Clara Soriano Award Lecture) // J. Neurol. Sci. - 2009; 285: 1-4.
  2. Jellinger K. Morphologic diagnosis of «vascular dementia» - a critical update. // J. Neurol. Sci. - 2008; 270: 1-12.
  3. Sachdev P., Kalaria R., O’Brien J. et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement // Alz. Dis. Ass. Dis. - 2014; 28: 206-18.
  4. Lim J., Kwon H. Risk of «silent stroke» in patients older than 60 years: risk assessment and clinical perspectives // Clin. Interv. Aging. - 2010; 5: 239-51.
  5. Чердак М.А., Яхно Н.Н. Нейродегенеративные и сосудистые факторы развития постинсультных когнитивных расстройств // Неврол. журн. - 2012; 17 (5): 10-5.
  6. Фонякин А.В, Гераскина Л.А. Артериальная ригидность, эндотелиальная функция и цереброваскулярные заболевания // Справочник поликлинического врача. - 2014; 4: 22-5.
  7. van Sloten T., Stehouwer C. Carotid stiffness: a novel cerebrovascular disease risk factor // Pulse (Basel). - 2016; 4: 24-7.
  8. Gorelick P., Scuteri A., Black S. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the Аmerican heart association/Аmerican stroke association // Stroke. - 2011; 42 (9): 2672-713.
  9. Farrall A., Wardlaw J. Blood-brain barrier: Ageing and microvascular disease - systematic review and meta-analysis // Neurobiol. Aging. - 2009; 30: 337-52.
  10. Hilal S., Sikking E., Shaik M. Cortical cerebral microinfarcts on 3T MRI: A novel marker of cerebrovascular disease // Neurology. - 2016; 87 (15): 1583-90.
  11. Daulatzai M. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease // J. Neurosci. Res. - 2016; 95 (4): 943-72.
  12. Мхитарян Э.А., Преображенская И.С. Болезнь Альцгеймера и цереброваскулярные расстройства // Неврол. журн. - 2006; 11 (1): 31-6.
  13. Чердак М.А., Успенская О.В. Сосудистая деменция // Неврол., нейропсихиат., психосомат. - 2010; 1: 30-6.
  14. Мхитарян Э.А. Значение сосудистых церебральных нарушений при болезни Альцгеймера. Дис.. канд. мед. наук / М., 2004.
  15. Matsui T., Nemoto M., Maruyama M. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease // Neurodegener. Dis. -2005; 2 (6): 299-304.
  16. Harrison S., Tang E., Keage H. et al. A systematic review of the definitions of vascular cognitive impairment, no dementia in cohort studies // Dement. Geriatr. Cogn. Disord. - 2016; 42 (1-2): 69-79.
  17. DeKosky S., Williamson J., Fitzpatrick A. et al. Ginkgo biloba for prevention of dementia. A randomized controlled trial // JAMA. - 2008; 300: 2253-62.
  18. Baskys A., Hou A. Vascular dementia: pharmacological treatment approaches and perspectives // Clin. Interv. Aging. - 2007; 2 (3): 327-35.
  19. Kavirajan H., Schneider L. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials // Lancet Neurol. - 2007; 6 (9): 782-92.
  20. Xi Y., Wang M., Zhang W. et al. Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion // Neurobiol. Learn. Mem. - 2014; 109: 7-19.
  21. Rammes G., Rupprecht R., Ferrari U. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner // Neurosci. Lett. - 2001; 306: 81-4.
  22. Вознесенская Т.Г. Эмоционально-аффективные и поведенческие нарушения при легких и умеренных когнитивных расстройствах. Опыт применения мемантина // Неврол. журн. - 2009; 14 (3): 49-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Russkiy Vrach Publishing House